Format

Send to

Choose Destination

See 1 citation found using an alternative search:

Cancer Res. 2012 Apr 1;72(7):1836-43. doi: 10.1158/0008-5472.CAN-11-2195. Epub 2012 Feb 6.

Rapamycin resistance is linked to defective regulation of Skp2.

Author information

1
Department of Physiology and Cellular Biophysics, the Clyde and Helen Wu Center for Molecular Cardiology, Columbia University College of Physicians & Surgeons, Columbia University, New York, USA. ht2167@columbia.edu

Abstract

The mammalian target of rapamycin (mTOR) plays a role in controlling malignant cellular growth. mTOR inhibitors, including rapamycin (sirolimus), are currently being evaluated in cancer trials. However, a significant number of tumors are rapamycin resistant. In this study, we report that the ability of rapamycin to downregulate Skp2, a subunit of the ubiquitin protein ligase complex, identifies tumors that are sensitive to rapamycin. RNA interference (RNAi)-mediated silencing of Skp2 in human tumor cells increased their sensitivity to rapamycin in vitro and inhibited the growth of tumor xenografts in vivo. Our findings suggest that Skp2 levels are a key determinant of antitumor responses to mTOR inhibitors, highlighting a potentially important pharmacogenomic marker to predict sensitivity to rapamycin as well as Skp2 silencing strategies for therapeutic purposes.

PMID:
22311674
PMCID:
PMC3690511
DOI:
10.1158/0008-5472.CAN-11-2195
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center